ArticlePloS one2026

Cost-utility analysis of lenvatinib and sorafenib for the first-line treatment of unresectable hepatocellular carcinoma in Vietnam: Evidence from a lower-middle income country.

Thang Xuan Do et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.